Pharvaris N.V.
PHVS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001830487
In the last 90 days, Pharvaris N.V. insiders filed 0 open-market purchases and 20 sales; 125 institutions reported holding it in 13F filings for Q2 2026, worth $2.23B in total; Viking Global Investors is the only superinvestor holding it.
13F holders, Q2 2021
Institutional positions in Pharvaris N.V. as of Jun 30, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 28
- −5 vs. Q1 2021
- Shares held
- 22.0M
- −29.3K (−0.1%) vs. Q1 2021
- Total value
- $406.3M
- −$210.2M (−34.1%) vs. Q1 2021
- New holders
- 2
- 9 more added
- Sold out
- 7
- 6 more reduced
Compare with Q1 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting PHVS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 125 | $2.23B |
| Q1 2026 | 110 | $1.67B |
| Q4 2025 | 106 | $1.64B |
| Q3 2025 | 83 | $1.44B |
| Q2 2025 | 60 | $792.7M |
| Q1 2025 | 52 | $705.5M |
| Q4 2024 | 54 | $855.8M |
| Q3 2024 | 51 | $834.2M |
| Q2 2024 | 36 | $808.6M |
| Q1 2024 | 35 | $980.5M |
| Q4 2023 | 36 | $1.14B |
| Q3 2023 | 21 | $606.6M |
| Q2 2023 | 21 | $441.6M |
| Q1 2023 | 21 | $173.9M |
| Q4 2022 | 25 | $239.6M |
| Q3 2022 | 21 | $173.6M |
| Q2 2022 | 20 | $494.0M |
| Q1 2022 | 22 | $397.1M |
| Q4 2021 | 22 | $321.1M |
| Q3 2021 | 25 | $380.3M |
| Q2 2021 | 28 | $406.3M |
| Q1 2021 | 33 | $616.5M |
Institutions, Q2 2021
Shares, value and share of portfolio for each institution holding Pharvaris N.V.; share changes are against Q1 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Bank of America Corp | 550 | $10.0K | 0.00% | +50+10.0% | Added |
| Tower Research Capital LLC (TRC) | 561 | $11.0K | 0.00% | +561 | New |
| Ensign Peak Advisors, Inc | 5,000 | $91.0K | 0.00% | 00.0% | Unchanged |
| Caas Capital Management LP | 13,479 | $251.0K | 0.01% | −36,521−73.0% | Reduced |
| Compagnie Lombard Odier SCmA | 15,030 | $274.0K | 0.01% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 16,434 | $299.0K | 0.00% | +2,560+18.5% | Added |
| Geode Capital Management, LLC | 18,643 | $338.0K | 0.00% | +2,259+13.8% | Added |
| Morgan Stanley | 19,984 | $372.0K | 0.00% | +15,149+313.3% | Added |
| Perceptive Advisors LLC | 27,000 | $503.0K | 0.01% | 00.0% | Unchanged |
| Goldman Sachs Group Inc | 27,792 | $518.0K | 0.00% | +3,364+13.8% | Added |
| BlackRock Inc. | 33,382 | $622.0K | 0.00% | 00.0% | Unchanged |
| Farallon Capital Management, L.L.C. | 71,020 | $1.29M | 0.01% | −128,980−64.5% | Reduced |
| Opaleye Management Inc. | 79,837 | $1.49M | 0.25% | +79,837 | New |
| Novo Holdings A/S | 111,144 | $2.07M | 0.09% | +61,144+122.3% | Added |
| Millennium Management LLC | 196,967 | $3.58M | 0.00% | −33,933−14.7% | Reduced |
| Foresite Capital Management V, LLC | 364,142 | $6.78M | 2.67% | −300,000−45.2% | Reduced |
| Avidity Partners Management LP | 400,000 | $7.45M | 0.20% | 00.0% | Unchanged |
| Eventide Asset Management, LLC | 541,563 | $9.84M | 0.13% | +41,563+8.3% | Added |
| Pictet Asset Management Ltd | 557,059 | $10.1M | 0.01% | +3,874+0.7% | Added |
| Cormorant Asset Management, LP | 744,863 | $13.6M | 0.53% | −119,280−13.8% | Reduced |
| VR Adviser, LLC | 902,882 | $16.8M | 2.04% | 00.0% | Unchanged |
| Deerfield Management Company, L.P. (Series C) | 1,032,757 | $19.2M | 0.34% | 00.0% | Unchanged |
| venBio Partners LLC | 2,303,310 | $42.9M | 5.06% | 00.0% | Unchanged |
| Viking Global Investors LPSuperinvestorViking Global Investors | 2,391,517 | $43.5M | 0.13% | −28,638−1.2% | Reduced |
| General Atlantic LLC | 2,420,155 | $45.1M | 0.32% | 00.0% | Unchanged |
| FMR LLC | 3,258,217 | $59.2M | 0.00% | +490,490+17.7% | Added |
| Bain Capital Life Sciences Investors, LLC | 3,180,601 | $59.3M | 3.88% | 00.0% | Unchanged |
| Foresite Capital Management IV, LLC | 3,261,926 | $60.8M | 8.21% | 00.0% | Unchanged |
| Marshall Wace North America L.P. | 0 | $0 | 0.00% | −39,008−100.0% | Sold out |
| Pinz Capital Management, LP | 0 | $0 | 0.00% | −22,650−100.0% | Sold out |
| Zimmer Partners, LP | 0 | $0 | 0.00% | −15,000−100.0% | Sold out |
| Davidson Kempner Capital Management LP | 0 | $0 | 0.00% | −3,500−100.0% | Sold out |
| Rokos Capital Management LLP | 0 | $0 | 0.00% | −2,500−100.0% | Sold out |
| Royal Bank of Canada | 0 | $0 | 0.00% | −116−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −32−100.0% | Sold out |